Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Debt (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Total Debt for 7 consecutive years, with $20.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Total Debt changed N/A to $20.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $20.4 million, a N/A change, with the full-year FY2019 number at $6.7 million, up 3991.29% from a year prior.
  • Total Debt was $20.4 million for Q2 2025 at Outlook Therapeutics, down from $21.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $21.0 million in Q1 2025 to a low of $20.4 million in Q2 2025.